Our History
Members matter ...
![HFM Members](https://hfmonline.org/wp-content/uploads/2024/02/HomePage-headshot3-square.png)
![HFM Members](https://hfmonline.org/wp-content/uploads/2024/02/HomePage-headshot2-square.png)
![HFM Members](https://hfmonline.org/wp-content/uploads/2024/02/HomePage-headshot4-square.png)
![HFM Members](https://hfmonline.org/wp-content/uploads/2024/02/HomePage-headshot5-square.png)
![HFM Members](https://hfmonline.org/wp-content/uploads/2024/02/HomePage-headshot6-square.png)
![HFM Members](https://hfmonline.org/wp-content/uploads/2024/02/HomePage-headshot7-square.png)
![45 fabulous ladies - HFM](https://hfmonline.org/wp-content/uploads/2024/03/Screen-Shot-2024-03-11-at-2.01.40-PM-300x293.png)
45 fabulous ladies help out
Conversation flows so easily among our ladies group, and there is so much we learn from each other during these incredible moments of connection.
![](https://hfmonline.org/wp-content/uploads/2024/06/FDA.png)
FDA Approval Includes Full ALTUVIIIO™ Pediatric Trial Results
The U.S. Food and Drug Administration (FDA) has approved updated prescribing information for ALTUVIIIO™ (Sanofi) to include the full results of the phase 3 XTEND-Kids clinical trial. ALTUVIIIO is a recombinant factor VIII therapy (rFVIII), developed with proprietary Fc fusion technologies to
Our History
Advocating for Marylanders since 1950
The Hemophilia Foundation of Maryland evolved in the early 1950’s from a group of concerned families. These early chapter families were brought together by the social worker at St. Agnes Hospital, where most were treated. Some of the founding members of this organization continue to guide HFM today.
Our Foundation's History of Advocacy
- Increasing awareness and understanding of bleeding disorders
- Advocating for a safe blood supply to ensure the integrity of clotting factor concentrates and other treatments for individuals with bleeding disorders
- Ensuring access to comprehensive care centers that provide specialized treatment and support services
- Advocating for affordable access to clotting factor concentrates and other essential medications
- Promoting research funding for innovative treatments
- Addressing disparities in healthcare access and quality for individuals with bleeding disorders, particularly in underserved communities
- Supporting policies that protect the rights of individuals with bleeding disorders, including anti-discrimination laws and healthcare coverage mandates
- Raising awareness about the challenges and needs of individuals living with a bleeding disorder to foster understanding and support within the broader community
- Collaborating with healthcare providers, researchers, policymakers, and advocacy organizations to advance the interests of bleeding disorder patients and improve their quality of life
- Promoting mental health support for bleeding disorder patients